Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings, Inc. (NYSE American: INFU) regularly issues news and press releases that are of interest to investors, analysts and others following the health care services and durable medical equipment space. The company describes itself as a national health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers, with operations organized into Patient Services and Device Solutions platforms.
News items about InfuSystem often include quarterly and annual financial results, where the company discusses net revenues, segment performance for Patient Services and Device Solutions, gross margin trends, cash flow, and Adjusted EBITDA. These releases typically highlight how oncology, pain management and wound therapy within Patient Services, as well as rentals, pump and consumable sales, and biomedical services within Device Solutions, have contributed to overall results.
Another common category of news involves guidance and outlook. InfuSystem has used press releases to provide or reaffirm guidance ranges for net revenue growth and Adjusted EBITDA margin for upcoming fiscal years, and to explain how factors such as revenue mix, information technology projects, and capital expenditures may affect margins and cash flow.
The company also issues announcements about leadership changes and corporate governance, such as the CEO transition disclosed in April 2025, and about participation in investor conferences hosted by firms like ROTH and Craig-Hallum. These items often note that management will host one-on-one or small group meetings with investors.
In addition, InfuSystem uses news releases to communicate regulatory and policy developments that affect its business. For example, an 8-K dated December 10, 2025 references a press release announcing that the Centers for Medicare and Medicaid Services added two electronic infusion pumps used in the company’s Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act.
Visitors to the INFU news page can review this stream of financial updates, guidance, leadership announcements, conference participation notices and regulatory disclosures to understand how the company describes its performance and strategic priorities over time.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national distribution agreement with Solo-Dex, Inc. for its continuous nerve block catheters, enhancing acute pain management capabilities. This technology allows anesthesiologists to insert catheters in two to three minutes for major procedures, potentially improving patient recovery while reducing reliance on opioids. The collaboration is aimed at capturing a significantly larger market, estimated to be ten times the current nerve catheter market. The joint effort aims to establish a new standard of care in pain management.
InfuSystem Holdings reported financial results for 2021, with net revenues at $102.4 million, a 5% increase from 2020. The fourth quarter saw revenues of $26.5 million, up 7.3% year-over-year. Despite this growth, net income dropped to $0.4 million, significantly lower than $10.7 million in Q4 2020. The gross margin decreased to 57.7%. Management anticipates 20% revenue growth in 2022, driven by pain management and a pending biomedical services contract expected to add $8-$12 million in revenue.
InfuSystem Holdings (NYSE: INFU) will announce preliminary fourth quarter and full year 2021 financial results on February 10, 2022, before the market opens. A conference call will follow the announcement at 9:00 a.m. Eastern Time to discuss these results. The company specializes in facilitating outpatient care for durable medical equipment through its Integrated Therapy Services and Durable Medical Equipment Services platforms. Interested parties can participate via phone or listen through a live webcast on the company’s investor relations website.
InfuSystem Holdings, Inc. (NYSE American: INFU) will present at the Sidoti Winter Virtual Investor Conference on January 19, 2022, at 8:30 a.m. ET. Key executives, including CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance, will lead the presentation.
A webcast will be available on their website, and a replay will follow the event. Investors can also engage in one-on-one meetings by contacting Lytham Partners.
InfuSystem Holdings (NYSE American: INFU) reported third-quarter 2021 net revenues of $26.6 million, a 6% increase year-over-year. The company anticipates $14-15 million in annual revenue from a new biomedical services contract, alongside growth in Pain Management services. Despite a net loss of $0.4 million and a 27% decline in Adjusted EBITDA, management is optimistic about future growth, reaffirming full-year revenue guidance of $107-110 million. Operating cash flow increased by 15% to $14.6 million.
InfuSystem Holdings, Inc. will release its Q3 2021 financial results on November 15, 2021, before market opens. A conference call is scheduled for the same day at 9:00 a.m. Eastern Time to discuss the results. Interested parties can participate by calling (833) 366-1127 or through a live webcast available on the company’s website. InfuSystem is a leading provider of health care services, focusing on integrated therapy services and durable medical equipment.
InfuSystem Holdings, Inc. (NYSE American: INFU) has entered into an exclusive three-year agreement with a major U.S. health care provider to offer its InfuBLOCK pain management therapy. This service includes electronic infusion pumps for post-surgical pain management, a 24/7 clinical hotline, and biomedical services. The agreement is expected to drive future revenue, leveraging InfuSystem’s expertise in outpatient care. The company emphasizes its non-narcotic pain management approach, aiming to enhance patient satisfaction while avoiding opioid-related risks.
InfuSystem Holdings (NYSE: INFU) announced its participation in Lake Street Capital Markets’ 5th Annual Best Ideas Growth (BIG5) Conference on September 14, 2021. CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will engage in one-on-one and group meetings with investors during the event. This invitation-only virtual conference features executive presentations from around 100 public growth companies and connects them with top institutional investors nationwide. InfuSystem provides outpatient care through Integrated Therapy Services and Durable Medical Equipment Services.
InfuSystem Holdings, Inc. (INFU) reported a Q2 2021 net revenue of $24.8 million, down 4% from the prior year. However, ITS segment revenue increased 5% to $16.3 million. Gross profit decreased 6% to $15.1 million, with a gross margin of 60.6%. Net income was $0.8 million, or $0.04/share, compared to $4.1 million or $0.19/share in Q2 2020. The company announced a $20 million stock repurchase program and revised its 2021 guidance to lower end estimates of $107 million to $110 million in net revenues.
InfuSystem Holdings (NYSE American: INFU) will release its second quarter 2021 financial results on August 12, 2021, before the market opens. The company, a leading provider of outpatient care for durable medical equipment, will host an investor conference call on the same day at 9:00 a.m. Eastern Time. Interested parties can join the call by dialing (833) 366-1127 or listening via a live webcast available on the company’s investor website. A replay will be accessible for 90 days post-call.